I see Henry Schein reported solid fiscal 2023 third-quarter results with revenues of $3.20 billion (+3.1% YoY) and particularly global dental sales grew 5.4% year-over-year.
We now know from Paul that its making Striate its leading product in its bone growth biologic as an adjunct to implants - we know the NIH reported 50% of implants having accompanying bone grafts in 2016 and this figure has long been trending higher with time as techniques improve.
I like the sales promotion:
https://www.biohorizons.com/Products/StriatePlus
Bio Horizons is marketing Sriate+ directly on its homepage, page-73
Add OCC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
39.0¢ |
Change
0.010(2.63%) |
Mkt cap ! $81.63M | |||
| Open | High | Low | Value | Volume |
| 37.5¢ | 39.0¢ | 37.5¢ | $49.66K | 129.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 20305 | 37.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.0¢ | 77938 | 2 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| OCC (ASX) Chart |